Equities analysts forecast that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) will report earnings per share of ($0.19) for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for BioCryst Pharmaceuticals’ earnings. The highest EPS estimate is ($0.16) and the lowest is ($0.21). BioCryst Pharmaceuticals reported earnings per share of ($0.22) during the same quarter last year, which would suggest a positive year over year growth rate of 13.6%. The company is expected to issue its next quarterly earnings report before the market opens on Monday, August 7th.

According to Zacks, analysts expect that BioCryst Pharmaceuticals will report full year earnings of ($0.72) per share for the current fiscal year, with EPS estimates ranging from ($0.83) to ($0.55). For the next year, analysts expect that the firm will report earnings of ($0.70) per share, with EPS estimates ranging from ($0.89) to ($0.46). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow BioCryst Pharmaceuticals.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Thursday, May 4th. The biotechnology company reported ($0.19) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.20) by $0.01. The company had revenue of $9.40 million for the quarter, compared to analyst estimates of $6.13 million. BioCryst Pharmaceuticals had a negative net margin of 150.24% and a negative return on equity of 323.86%. The firm’s revenue for the quarter was up 95.8% on a year-over-year basis. During the same period in the prior year, the company posted ($0.31) EPS.

Several equities research analysts recently issued reports on BCRX shares. Noble Financial reissued a “buy” rating on shares of BioCryst Pharmaceuticals in a research report on Saturday, May 6th. Zacks Investment Research upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price target for the company in a research note on Monday, May 1st. Finally, Needham & Company LLC reiterated a “hold” rating on shares of BioCryst Pharmaceuticals in a report on Friday, May 19th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $8.29.

Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) traded down 3.08% on Tuesday, hitting $5.04. 830,061 shares of the company traded hands. BioCryst Pharmaceuticals has a 12 month low of $2.95 and a 12 month high of $9.25. The company’s market capitalization is $405.32 million. The stock’s 50-day moving average price is $5.67 and its 200-day moving average price is $6.42.

COPYRIGHT VIOLATION NOTICE: This piece of content was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/07/25/0-19-eps-expected-for-biocryst-pharmaceuticals-inc-nasdaqbcrx-this-quarter.html.

A number of large investors have recently made changes to their positions in BCRX. Principal Financial Group Inc. raised its stake in shares of BioCryst Pharmaceuticals by 0.3% in the first quarter. Principal Financial Group Inc. now owns 13,250 shares of the biotechnology company’s stock worth $111,000 after buying an additional 45 shares in the last quarter. Comerica Bank raised its stake in shares of BioCryst Pharmaceuticals by 18.8% in the fourth quarter. Comerica Bank now owns 16,105 shares of the biotechnology company’s stock worth $100,000 after buying an additional 2,552 shares in the last quarter. Fox Run Management L.L.C. purchased a new stake in shares of BioCryst Pharmaceuticals during the second quarter worth about $126,000. Bank of America Corp DE raised its stake in shares of BioCryst Pharmaceuticals by 43.3% in the first quarter. Bank of America Corp DE now owns 25,029 shares of the biotechnology company’s stock worth $210,000 after buying an additional 7,568 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in shares of BioCryst Pharmaceuticals during the first quarter worth about $337,000. 84.57% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.